profit from every $100 of sales.
$0$100
Rani Therapeutics Holdings
$0.53+0.21% today
-72.7% in 1 year
1-year low $0.521-year high $1.94
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Rani Therapeutics Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $1.63 million in 2025, with -$29.7 million of profit last year.
SalesProfit
Rani Therapeutics Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Rani Therapeutics Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Rani Therapeutics Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 2 | |
| – | – | – | – | |
| -63 | -66 | -50 | -38 | |
| -62 | -62 | -51 | -37 | |
| -31 | -34 | -30 | -30 | |
| -1.28 | -1.33 | -1.05 | -0.45 | |
| – | – | – | – | |
| – | – | -4,824.9% | -2,346.0% | |
| – | – | -2,920.0% | -1,817.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 108 | 58 | 37 | 59 |
| Cash | 27 | 6 | 4 | 19 |
| Total debt | 30 | 30 | 30 | 4 |
| Total liabilities | 34 | 32 | 33 | 17 |
| 37 | 13 | 2 | 33 | |
| 24 | 26 | 28 | 66 | |
| -73.3% | -115.5% | -128.5% | -80.5% | |
| -83.0% | -264.0% | -1,506.9% | -89.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -47 | -51 | -35 | -19 | |
| 2 | 1 | 0 | 0 | |
| -48 | -52 | -36 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 16 | 19 | 16 | 12 |
Valuation
- –
- –
- –
- 4.3×
- 45.3×
- –
- –
- -25.4%
- -40.1%
- 0.0%
Profitability
- 75.0%
- -2,346.0%
- -1,817.1%
- -2,290.9%
- -80.6%
- -63.3%
- -718.5%
- -50.6%
- -83.4%
- 1,237.2%
Growth
- +58.9%
- –
- +47.4%
- –
- +35.6%
Financial health
- -0.4×
- 0.13
- 7.4%
- -13.3×
- 4.21
- 4.21
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Top 9%of 886
Bottom 3%of 987
What analysts expect
- Average price target
- $15.67
- Range
- $9.00 – $28.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.04 | -0.06 | +33.3% |
| Mar 26, 2026 | -0.07 | -0.03 | −133.3% |
| Nov 6, 2025 | -0.12 | -0.09 | −33.3% |
| Aug 7, 2025 | -0.18 | -0.19 | +5.3% |
| May 13, 2025 | -0.22 | -0.22 | +0.0% |
| Mar 31, 2025 | -0.27 | -0.24 | −12.5% |
| Nov 14, 2024 | -0.24 | -0.22 | −9.1% |
| Aug 6, 2024 | -0.26 | -0.29 | +10.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
39No pass
Philip Fisher
55No pass
Peter Lynch
98Pass
Joel Greenblatt
0No pass
Charlie Munger
50No pass
Terry Smith
48No pass
Questions about Rani Therapeutics Holdings
Is Rani Therapeutics Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Rani Therapeutics Holdings AI analysis
What does Rani Therapeutics Holdings do?
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. It is in Biotechnology.
Does Rani Therapeutics Holdings pay a dividend?
No. Rani Therapeutics Holdings does not pay a dividend at the moment.
Is Rani Therapeutics Holdings stock halal?
Questionable. Rani Therapeutics Holdings sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Rani Therapeutics Holdings stock done over the past year?
Down 72.7% over the past twelve months, to $0.53. It traded between $0.52 and $1.94 and is 72.9% below its high.
Who are Rani Therapeutics Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Rani Therapeutics Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.